# The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

Source: https://onco.cc/trials/nct04329728/  
OnCo record `nct04329728` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AVM0703 in advanced solid tumours, run by AVM Biotechnology Inc, now recruiting.

## Summary

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies is a phase 1/2 interventional study registered as NCT04329728 by AVM Biotechnology Inc, with 144 participants planned, started 2020-11-06 and due to reach its primary completion in 2027-11-30. Interventions recorded: AVM0703.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04329728
- Phase: 1/2
- Setting: An Open Label, Phase 1/2 Study Evaluating Immunomodulatory AVM0703 in Patients With Lymphoid Malignancies (OPAL Study)
- Sponsor: AVM Biotechnology Inc
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT04329728: https://clinicaltrials.gov/study/NCT04329728

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Medpace](https://onco.cc/companies/medpace/)

---
JSON: https://onco.cc/api/v1/entities/nct04329728.json